Discover CTSim™
CTSim™ leverages quantum computing algorithms to revolutionize early-stage drug development by exploring billions of molecular combinations simultaneously
The Challenge
Traditional methods cost billions and take decades
Our Solution
Quantum-Powered Drug Design
Revolutionary capabilities that transform molecular discovery
Quantum Molecular Exploration
Explore billions of molecular combinations simultaneously using quantum algorithms that exceed classical computational limits.
>90% Prediction Accuracy
Achieve >90% drug-target binding accuracy compared to 60-70% with traditional methods, improving success rates.
AI Lead Optimization
Automatically refine molecular structures for enhanced efficacy, selectivity, and reduced toxicity using machine learning.
Pre-Synthesis Safety Screening
Identify safety concerns before synthesis, eliminating problematic candidates early and reducing development costs.
Platform Capabilities
Technology
Proprietary Technology Stack
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
Python Ecosystem
TensorFlow/PyTorch
Advanced CNNs
HIPAA Compliant
Cloud Native
Multi-Platform
Our Difference
CTSim™
Chemical Space Exploration
Molecular combination screening
Limited subset manual screening
Billions of compounds analyzedutes
Molecular Interaction Prediction
Drug-target binding accuracy
Classical models (60-70% accuracy)
Quantum-precise modeling (>90%)
Lead Optimization
Compound refinement for efficacy
Iterative manual testing
AI-driven automated optimization
Early Liability Detection
Adverse effect prediction
Late-stage discovery
Pre-synthesis prediction
Development Timeline
Early-stage discovery to lead
10-15 years
Months for lead candidates
Development Cost
Early-stage R&D investment
$2.6B per drug
60-70% cost reduction
Clinical Trial Success Rate
Candidate progression probability
<12%
Projected 25-30% improvement
Synthesis Route Planning
Manufacturing pathway efficiency
Manual design
Quantum-optimized routes
Discovery Throughput
Novel candidate identification rate
Dozens per year
Hundreds per month
T. Ritchie
Chief Executive Officer
Managing a multi-billion dollar investment fund, 25+ years in business development and leadership.
Dr. Alex F. Metwaly
Co-Founder & Chief Scientific Officer
20+ years in BioTech and AI, Former Chair of National Data Center, 150+ publications in deep learning.
Dr. F. A. Naftolin
Chief Medical Officer
MD, PhD in Women's Health, Expert in drug design, clinical trials, and healthcare strategy.
P. Wolfe
Board Head
Managing Partner at top-tier VC firm, 30+ years in strategic technology investments and growth scaling.
James Wilson
Head of Business Development
Former VP at Siemens Healthineers, 20+ years in medical device commercialization and global sales.
TBN
Head of Sales (Recruiting)
Candidate search underway for experienced sales leader with deep hospital and health system network.
Confidential Material
This section contains proprietary information intended for potential investors.
Market Opportunity
Born from the collective ambition of industry veterans and technology innovators, our mission is to expedite the journey of groundbreaking healthcare solutions from conception to global markets.
Confidential Material
This section contains proprietary information intended for potential investors.
Technology
Proprietary Technology Stack
Built on cutting-edge AI research with robust, secure, and scalable clinical-grade infrastructure.
$
10M
Series A (Projected)
Targeted capital for full commercial scaling, regulatory approvals, and platform module expansion.
EU MDR & full FDA 510(k) clearance
Expansion to 50+ hospital systems globally
Development of 3 new specialty AI modules
International market penetration
Ready to See the Full Picture?
This section contains proprietary information intended for potential investors.